Previous Close | 21.16 |
Open | 21.07 |
Bid | 16.00 x 800 |
Ask | 28.01 x 900 |
Day's Range | 20.99 - 21.71 |
52 Week Range | 13.82 - 24.21 |
Volume | |
Avg. Volume | 651,563 |
Market Cap | 1.944B |
Beta (5Y Monthly) | 1.96 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.18 |
Earnings Date | May 01, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.36 |
Subscribe to Yahoo Finance Plus to view Fair Value for MYGN
Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Myriad Genetics ( NASDAQ:MYGN ) Full Year 2023 Results Key Financial Results Revenue: US$753.2m (up 11% from FY 2022...